Serine hydroxymethyl transferase 1 stimulates pro-oncogenic cytokine expression through sialic acid to promote ovarian cancer tumor growth and progression

• Published in: Oncogene 2017-07, Vol.36 (28), p.4014-4024
• Main Authors: Gupta, R, Yang, Q, Dogra, S K, Wajapeyee, N
• Format: Article
• Language: English
• Subjects: 13/95; 38/39; 631/67/68; 631/67/69; 82/58; Animals; Apoptosis; Carcinogenesis - genetics; Carcinogenesis - metabolism; Carcinogenesis - pathology; Cell adhesion & migration; Cell Biology; Cell culture; Cell Line, Tumor; Cell migration; Cell Proliferation - genetics; Cystadenocarcinoma, Serous - genetics; Cystadenocarcinoma, Serous - metabolism; Cystadenocarcinoma, Serous - pathology; Cytokines; Cytokines - genetics; Cytokines - metabolism; Development and progression; Disease Progression; Enzymes; Female; Folic acid; Gene expression; Gene Expression Regulation, Neoplastic; Genomes; Glycine Hydroxymethyltransferase - physiology; Growth inhibition; Health aspects; HEK293 Cells; Human Genetics; Humans; Inflammation; Inflammation Mediators - metabolism; Interleukin 6; Interleukin 8; Internal Medicine; Medicine; Medicine & Public Health; Metabolic pathways; Metabolism; Metabolites; Metabolomics; Mice; Mice, Nude; N-Acetylneuraminic acid; N-Acetylneuraminic Acid - metabolism; Oncology; Original; original-article; Ovarian cancer; Ovarian Neoplasms - genetics; Ovarian Neoplasms - metabolism; Ovarian Neoplasms - pathology; Properties; Serine; Serine hydroxymethyltransferase; Sialic acids; Sugar; Supplements; WT1 protein
• ISSN: 0950-9232; 1476-5594
• DOI: 10.1038/onc.2017.37

High-grade serous (HGS) ovarian cancer accounts for 90% of all ovarian cancer-related deaths. However, factors that drive HGS ovarian cancer tumor growth have not been fully elucidated. In particular, comprehensive analysis of the metabolic requirements of ovarian cancer tumor growth has not been performed. By analyzing The Cancer Genome Atlas mRNA expression data for HGS ovarian cancer patient samples, we observed that six enzymes of the folic acid metabolic pathway were overexpressed in HGS ovarian cancer samples compared with normal ovary samples. Systematic knockdown of all six genes using short hairpin RNAs (shRNAs) and follow-up functional studies demonstrated that serine hydroxymethyl transferase 1 (SHMT1) was necessary for ovarian cancer tumor growth and cell migration in culture and tumor formation in mice. SHMT1 promoter analysis identified transcription factor Wilms tumor 1 (WT1) binding sites, and WT1 knockdown resulted in reduced SHMT1 transcription in ovarian cancer cells. Unbiased large-scale metabolomic analysis and transcriptome-wide mRNA expression profiling identified reduced levels of several metabolites of the amino sugar and nucleotide sugar metabolic pathways, including sialic acid N -acetylneuraminic acid (Neu5Ac), and downregulation of pro-oncogenic cytokines interleukin-6 and 8 (IL-6 and IL-8) as unexpected outcomes of SHMT1 loss. Overexpression of either IL-6 or IL-8 partially rescued SHMT1 loss-induced tumor growth inhibition and migration. Supplementation of culture medium with Neu5Ac stimulated expression of IL-6 and IL-8 and rescued the tumor growth and migratory phenotypes of ovarian cancer cells expressing SHMT1 shRNAs. In agreement with the ovarian tumor-promoting role of Neu5Ac, treatment with Neu5Ac-targeting glycomimetic P-3Fax-Neu5Ac blocked ovarian cancer growth and migration. Collectively, these results demonstrate that SHMT1 controls the expression of pro-oncogenic inflammatory cytokines by regulating sialic acid Neu5Ac to promote ovarian cancer tumor growth and migration. Thus, targeting of SHMT1 and Neu5Ac represents a precision therapy opportunity for effective HGS ovarian cancer treatment.